Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Anti-idiotypic
Reexamination Certificate
2003-04-08
2010-06-29
Ewoldt, G. R (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Anti-idiotypic
C424S133100, C530S387100
Reexamination Certificate
active
07744876
ABSTRACT:
The present invention relates generally to methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes. More specifically, the present invention relates to the administration of a fusion protein comprising at least one immunoglobulin having one or more diabetogenic epitopes inserted within the variable region, for suspending, preventing or delaying the onset of type 1 diabetes.
REFERENCES:
patent: 5817308 (1998-10-01), Scott et al.
patent: 5969109 (1999-10-01), Bona et al.
patent: 6737057 (2004-05-01), Zaghouani
patent: 2002/0038002 (2002-03-01), Zaghouani
patent: 2002/0081298 (2002-06-01), Zaghouani
patent: 2003/0103967 (2003-06-01), Zaghouani
patent: 2005/0031605 (2005-02-01), Bunn et al.
patent: 2005/0037448 (2005-02-01), Bouanani et al.
patent: 2006/0115478 (2006-06-01), Zaghouani
patent: 0741788 (2005-02-01), None
patent: 9009804 (1990-09-01), None
patent: WO9009804 (1990-09-01), None
patent: 9521926 (1995-08-01), None
patent: 9830706 (1998-07-01), None
patent: 9932136 (1999-07-01), None
patent: 2004004642 (2004-01-01), None
Liu, C.-P., et al. PNAS, 2000;97(26):14596-14601.
Balasa, B., et al., “A Mechanism for IL-10-Mediated Diabetes in the Nonobese Diabetic (NOD) Mouse: ICAM-1 Deficiency Blocks Accelerated Diabetes,” The Journal of Immunology, vol. 165, pp. 7330-7337 (2000).
Bu, Ding-Fang, et al., “Two Human Glutamate Decarboxylases, 65-kDa GAD and 67-kDa GAD, Are Each Encoded by a Single Gene,” Proc. Natl. Acad. Sci. USA, vol. 89, pp. 2115-2119 (1992).
Gregg, Randal, et al., “IL-10 Diminishes CTLA-4 Expression on Islet-Resident T Cells and Sustains Their Activation Rather Than Tolerance,” The Journal of Immunology, vol. 174, pp. 662-670 (2005).
Gregg, Randal, et al., “A Sudden Decline in Active Membrane-Bound TGF-β Impairs Both T Regulatory Cell Function and Protection Against Autoimmune Diabetes,” The Journal of Immunology, vol. 173, pp. 7308-7316 (2004).
Kaufman, D., et al., “Autoimmunity to Two Forms of Glutamate Decarboxylase in Insulin-Dependent Diabetes Mellitus,” Journal of Clinical Investigation, vol. 89, pp. 283-292 (1992).
Legge, K., et al., “Coupling of Peripheral Tolerance to Endogenous Interleukin 10 Promotes Effective Modulation of Myelin-Activated T Cells and Ameliorates Experimental Allergic Encephalomyelitis,” J. Exp. Med., vol. 191, No. 12, pp. 2039-2051 (2000).
Legge, K., et al., “Multi-Modal Antigen Specific Therapy for Autoimmunity,” Intern. Rev. Immunol., vol. 20, pp. 593-611 (2001).
Zambidis, E., et al., “Epitope-Specfic Tolerance Induction with An Engineered Immunoglobulin,” Proc. Natl. Acad. Sci. USA, Immunology, vol. 93, pp. 5019-5024 (1996).
Marketletter, “AutoImmune Shares Collapse on Colloral Data in Rheumatoid Arthritis,” Sep. 13, 1999, Marketletter Publications Ltd.
Anderton, Stephen M., “Peptide-Based Immunotherapy of Autoimmunity: A Path of Puzzles, Paradoxes and Possibilities.” Immunology 2001; 104: 367-376.
Legge, Kevin L., et al., “TCR Agonist and Antagonist Exert in Vivo Cross-Regulation When Presented on Igs.” J. Immunology 1998; 161: 106-111.
Dong, VM, et al., “Transplantation Tolerance: The Concept and Its Applicability.” Ped. Transplan. 1999; 3 181-192.
Harrison, L. “Vaccination Against Self to Prevent Autoimmune Disease: The Type 1 Diabetes Model.” Immunology and Cell Biology. 2008; 86: 139-145.
Couzin, J. “Diabetes' Brave New World.” Science. 2003; 300: 1862-1865.
Alleva, D.G., A. Gaur, L. Jin, D. Wegmann, P.A. Gottlieb, A. Pahuja, E.B. Johnson, T. Motheral, A. Putnam, P.D. Crowe, N. Ling, S.A. Boehme, and P.J. Conlon. (2002). Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI6024, based on the immunodominant type 1 diabetes autoantigen insulin 13-chain (9-23) peptide.Diabetes. 51: 2126-2134.
Andre, I., A. Gonzalez, B. Wang, J. Katz, C. Benoist, and D. Mathis. 1996. Checkpoints in the progression of autoimmune disease: lessons from diabetes models.Proc. Natl. Acad. Sci. USA. 93:2260-2263.
Asseman, C., S. Mauze, M. W. Leach, R. L. Coffman, and F. Powrie. 1999. An essential role for IL-10 in the function of regulatory T cells that inhibit intestinal inflammation.J. Exp. Med190:995-1004.
Bach, J.F. 1994. Insulin-dependent diabetes mellitus as an autoimmune disease.Endroc. Rev. 15:516-542.
Balasa, B., and N. Sarvetnick. 1996. The paradoxical effects of interleukin 10 in the immunoregulation of autoimmune diabetes.Autoimmun. 9:283-286.
Barrat, F.J., D.J. Cua, A. Boonstra, D.F. Richards, C. Crain, H.F. Savelkoul, R. de WaalMalefyt, R.L. Coffman, C.M. Hawrylowicz, and A. O'Garra. 2002. In vitro generation of interleukin 10-producing regulatory CD4+T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines.J Exp. Med. 195:603-616.
Bonifacio, E., M. Atkinson, G. Eisenbarth, D. Serreze, T.W. Kay, E. Lee-Chan, and B. Singh. 2001. International workshop on lessons from animal models for human type 1 diabetes: identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice.Diabetes. 50:2451-2458.
Bot, A., D. Smith, S. Bot, A. Hughes, T. Wolfe, L. Wang, C. Woods, and M. von Herrath. 2001. Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice.J. Immunol. 176: 2950-2955.
Brumeanu, T.D., W.J. Swiggard, R.M. Steinman, C.A. Bona, and H. Zaghouani. 1993. Efficient loading of identical viral peptide onto class II molecules by antigenized immunoglobulin and influenza virus.J. Exp. Med. 178:1795-1799.
Buschard, K., T. Bock, C.R. Pederson, S.V. Hansen, K. Aaen, M. Jorgenson, M.W. Hansen, T.W. Kjaer, I. Hageman, and K. Josefsen. 2000. Neonatal treatment with beta-cell stimulatory agents reduces the incidence of diabetes in BB rats.Int. Exp. Diabetes Res. 1:1-8.
Castano, L., and G.S. Eisenbarth. 1990. Type-1 diabetes: a chronic autoimmune disease of human, mouse, and rat.Ann Rev. Immunol. 8:647-680.
Christen, U., T. Wolfe, U. MOhrle, A.C. Hughes, E. Rodrigo, E.A. Green, R.A. Flavell, and M.G. von Herrath. 2001. A dual role for TNF-a in type I diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis.J. Immunol. 166:7023-7032.
Christian, C.L. 1960. Studies on aggregated gamma-globulin I & II.J. Immunol. 84:112-121.
Daniel, D., and D.R. Wegmann. 1996. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B (9-23).Proc. Natl. Acad. Sci. USA. 93:956-960.
Delovitch, T., and B. Singh. 1997. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD.Immunity. 7:727-738.
Dotta, Francesco, Marcello Previti, Marguerite Neerman-Arbez, Sabrina Dionisi, Domenico Cucinotta, Luisa Lenti, Umberto DiMario, The GM2-1 Ganglioside Islet Autoantigen in Insulin-Dependent Diabetes Mellitus is Expressed in Secretory Grnaules and is Not β-Cell Specific,Endocrinology, 139(1):316-319, 1998.
Faveeuw, C., M.C. Gagnerault, and F. Lepault. 1995. Isolation of leukocytes infiltrating the islets of Langerhans of diabetes-prone mice for flow cytometric analysis.J. Immunol. Methods. 187:163-169.
Gottlieb, P.A., and G.S. Eisenbarth. 2002. Insulin-specific tolerance in diabetes.Clin. Immunol. 102:2-11.
Groux, H., A. O'Garra, M. Bigler, M. Rouleau, J. de Vries, and M.-G. Roncarolo. 1997. Generation of a novel regulatory CD4+ T-cell population, which inhibits antigen-specific T-cell responses.Nature. 389:737-742.
Heath, V.L., P. Hutchings, D.J. Fowell, A. Cooke, and D. Mason. 1999. Peptides derived from murine insulin are diabetogenic in both rats and mice, but the disease-inducing epitopes are different: evidence against a common environmental cross-reactivity in the pathogenicity of type I diabetes.Diabetes. 48:2157-2165.
Honeyman, Margo C, Natalie L. S
Gregg Randal Keith
Zaghouani Habib
Ewoldt G. R
K&L Gates LLP
The Curators of the University of Missouri
LandOfFree
Methods and compositions for treatment, prevention,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treatment, prevention,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treatment, prevention,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4246357